Pharmaceutical industry bristles under FDA draft guidance
The amount of FDA draft guidance in play during the past few months has drawn skepticism from the pharmaceutical industry, which has its own thoughts on how best to address the broad scope of the agency’s proposed authority. Jaclyn Jaeger reports.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
ArticleThe compliance side of the war on drugs
In a precedent-setting case, drugmaker Mallinckrodt Pharmaceuticals has agreed to a $35 million settlement with the U.S. federal government for failing to monitor its sales channels for suspicious orders.
-
Article
The EpiPen controversy’s bad omens for pharmas
At a recent hearing with the CEO of Mylan, the maker of EpiPen, legislators hinted at not only price controls, but an increased scrutiny of executive pay. Joe Mont has more.
-
Article
European Medicines Agency issues data integrity guidance
The pharmaceutical industry faces fresh regulatory pressure around the world over data integrity issues, reports Jaclyn Jaeger, particularly involving clinical trials.